A detailed history of Jennison Associates LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 237,745 shares of EDIT stock, worth $311,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares
237,745
Previous 124,888 90.37%
Holding current value
$311,445
Previous $583,000 38.94%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$3.39 - $5.96 $382,585 - $672,627
112,857 Added 90.37%
237,745 $810,000
Q2 2024

Aug 05, 2024

BUY
$4.67 - $7.28 $85,778 - $133,719
18,368 Added 17.24%
124,888 $583,000
Q1 2024

May 02, 2024

BUY
$7.03 - $11.07 $168,720 - $265,680
24,000 Added 29.08%
106,520 $790,000
Q4 2023

Feb 01, 2024

SELL
$6.25 - $11.11 $64,250 - $114,210
-10,280 Reduced 11.08%
82,520 $835,000
Q3 2023

Oct 31, 2023

SELL
$6.92 - $9.31 $172,868 - $232,573
-24,981 Reduced 21.21%
92,800 $723,000
Q2 2023

Aug 03, 2023

BUY
$6.36 - $11.47 $139,455 - $251,502
21,927 Added 22.88%
117,781 $969,000
Q1 2023

Apr 26, 2023

BUY
$7.03 - $11.53 $20,928 - $34,324
2,977 Added 3.21%
95,854 $694,000
Q4 2022

Feb 09, 2023

BUY
$8.32 - $13.21 $303,538 - $481,940
36,483 Added 64.69%
92,877 $823,000
Q3 2022

Nov 01, 2022

SELL
$12.16 - $19.42 $89,740 - $143,319
-7,380 Reduced 11.57%
56,394 $690,000
Q2 2022

Aug 02, 2022

BUY
$9.99 - $21.35 $110,499 - $236,152
11,061 Added 20.98%
63,774 $754,000
Q1 2022

May 11, 2022

BUY
$14.08 - $27.63 $742,199 - $1.46 Million
52,713 New
52,713 $1 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.